CD274 and non-small cell lung carcinoma: Immune checkpoint inhibitors (ICIs), particularly with therapeutic antibodies targeting programmed-death ligand 1 (PD-L1)/PD-1, are currently the backbone of first-line therapy in patients with advanced NSCLC without driver oncogenes [67,68].